Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor

Michael Winkelmann1, Veit L Bücklein2, Viktoria Blumenberg2

  • 1Department of Radiology, University Hospital, Ludwig Maximilian University (LMU) Munich, Munich, Germany.

Frontiers in Oncology
|September 26, 2022
PubMed
Abstract

Related Concept Videos